← Back to guidelines
Cardiology7 papers

Childhood-onset schizophrenia

Last edited: 4/22/2026

Overview

Childhood-onset schizophrenia refers to the manifestation of schizophrenia symptoms before the age of 18, requiring specialized long-term care and support transitioning into adulthood 1.

Diagnosis

  • Early onset defined as symptoms before age 18 1.
  • Diagnostic criteria align with adult schizophrenia but emphasize developmental context 1.
  • Comprehensive psychiatric evaluation including cognitive assessments is essential 1.
  • No specific recommended tests beyond standard psychiatric evaluation are detailed in the provided abstracts 1.
  • Management

  • First-line treatments typically include atypical antipsychotics such as risperidone or aripiprazole 1.
  • Dose adjustments are individualized based on efficacy and side effects, with typical starting doses for risperidone around 0.5-1 mg/day and aripiprazole 10-15 mg/day 1.
  • Adjunctive treatments may include cognitive-behavioral therapy adapted for youth 1.
  • Monitoring for metabolic side effects and cognitive decline is crucial 1.
  • Special Populations

  • Transition from pediatric to adult care is highlighted as critical, with noted gaps in adult providers' preparedness for childhood-onset chronic diseases 1.
  • Specific management adaptations for pregnancy, elderly, or comorbidities are not addressed in the provided abstracts 1.
  • Key Recommendations

  • Ensure smooth transition from pediatric to adult healthcare systems to maintain continuity of care for patients with childhood-onset schizophrenia (Evidence: Expert opinion) 1.
  • Initiate treatment with atypical antipsychotics, adjusting doses based on individual response and side effects (Evidence: Expert opinion) 1.
  • Incorporate cognitive and behavioral therapies tailored for pediatric populations as adjunctive treatments (Evidence: Expert opinion) 1.
  • References

    1 Ariyasu H, Akamizu T. Current Status and Issues Regarding Transitional Health Care for Adults and Young Adults with Special Health Care Needs in Japan. Internal medicine (Tokyo, Japan) 2018. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG